Research Papers:
Significant prognostic value of circulating tumor cells in esophageal cancer patients: A meta-analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2639 views | HTML 2336 views | ?
Abstract
Shuyu Wang1, Hongyang Du2, Guixia Li1
1Medical Laboratory Department, Heze Municipal Hospital, Heze, Shandong, 274031 China
2Heze Centre for Adverse Drug Reactions Monitoring, Heze, Shangdong, 274000, China
Correspondence to:
Shuyu Wang, email: [email protected]
Keywords: esophageal cancer, circulating tumor cells, meta-analysis
Received: July 10, 2016 Accepted: January 03, 2017 Published: February 02, 2017
Abstract
Esophageal cancer is the sixth leading cause of cancer death worldwide. Detection of circulating tumor cells (CTCs) is emerging as a novel strategy for predicting cancer patient prognosis. Here we performed a comprehensive literature search to identify relevant articles in EMbase, PubMed, EBSCO, OVID, Cochrane Database, CNKI, WanFangdata and VIPdata. Meta-analysis was conducted using Stata12.0 software, according to the inclusion and exclusion criteria, extracted data and assessment methodology. Thirteen eligible literature studies were included with a total of 979 esophageal squamous cell carcinoma patients, including 424 CTC-positive and 684 CTC-negative cases. Meta-analysis showed that the presence of CTCs was associated with both worse progression-free/disease-free survival [hazard ration (HR) = 2.32, 95% confidence interval (CI) = 1.57 - 3.43, p < 0.001] and poorer overall survival [HR = 2.64, 95% CI = 1.69 - 4.14, p < 0.001]. Further subgroup analyses demonstrated that CTC-positive patients also showed worse progression-free/disease-free survival and poorer overall survival in different subsets. In summary, our meta-analysis provides strong evidence that detection of CTCs in the peripheral blood is an independent prognostic indicator of poor outcome for esophageal squamous cell carcinoma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15012